No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration

BACKGROUND: Although ranibizumab has been used for the treatment of wet age-related macular degeneration (AMD) since 2007, real-world studies still report undertreatment resulting in a less favorable visual outcome. In this study, two different time cohorts of patients treated with ranibizumab for w...

Descripción completa

Detalles Bibliográficos
Autores principales: Schroeder, Marion, Rung, Lena, Lövestam-Adrian, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472435/
https://www.ncbi.nlm.nih.gov/pubmed/28652696
http://dx.doi.org/10.2147/OPTH.S130182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472435/
https://www.ncbi.nlm.nih.gov/pubmed/28652696
http://dx.doi.org/10.2147/OPTH.S130182

Ejemplares similares